Rituximab manufacturers and suppliers

Rituximab suppliers

Rituximab

CAS:

MF:

MW:: 0

Suppliers by country/region

Company Type

Properties

Safety Information

Use

Rituximab (Rituxan, Chimeric) is an MAb directed againstthe CD20 antigen expressed on the surfaces of normal andmalignant B lymphocytes. The MAb is produced in mammalian(CHO) suspension culture and is a chimeric(murine/human) MAb of the IgG1 κ type. The protein is composed of murine light and heavy chain variable regionsand human constant regions. Rituximab is indicated for thetreatment of patients with relapsed or refractory, low-gradeor follicular, CD20(+) B-cell non-Hodgkin lymphoma.Rituximab binds specifically to antigen CD20 (human Blymphocyte–restricted differentiation antigen, a hydrophobictransmembrane protein expressed on pre-B and matureB lymphocytes). CD20 is a protein of 35 to 37 kDa, and itmay play a role in B cell activation and regulation and maybe a calcium ion channel. The antigen is also expressed onmore than 90% of non-Hodgkin lymphoma B cells but is notfound on hematopoietic stem cells, pro-B cells, normalplasma cells, or other normal tissues. CD20 regulates theearly steps in the activation process for cell cycle initiationand differentiation.

You can find Rituximab suppliers, manufacturers, and distributors from countries such as China, Europe and the India here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.